Retrospective evaluation of labetalol as antihypertensive agent in

Background To evaluate the effect on arterial blood pressure (ABP) of labetalol infusion as treatment for perioperative non nociceptive acute hypertension in dogs. The clinical records of dogs receiving intra or postoperative labetalol infusion were retrospectively reviewed. Invasive systolic (SAP), mean (MAP) and diastolic (DAP) arterial pressure and heart rate (HR) before labetalol infusion (T0) and 15, 30, 45 and 60 min (T1, T2, T3 and T4 respectively) after infusion were retrieved. The dose rate of labetalol infusion and use of concurrently administered drugs that could have potentially affected ABP and/or HR were also recorded. ANOVA for repeated measures and Dunnett’s multiple comparison test were used to determine the effect of labetalol on ABP and HR. Differences were considered significant when p < 0.05. Results A total of 20 dogs met the inclusion criteria, and hypertension was documented after craniotomy (12/20), adrenalectomy (4/20) and other procedures (4/20). Five dogs received labetalol intraoperatively, 14 postoperatively, and 1 during the surgical procedure and recovery. Median infusion duration and rate were 463 (60-2120) minutes and 1.1 (0.2–3.4) mg/kg/h respectively. Median loading dose was 0.2 (0.2–0.4) mg/kg. Labetalol produced a significant decrease in SAP and DAP at all time points compared to T0 (p < 0.05), while the effect was not significant at T1 for MAP (p = 0.0519). Median maximum MAP decrease was 31 (20–90) mmHg. Heart rate did not increase significantly during treatment (p = 0.2454). Acepromazine given before or during labetalol treatment did not reduce significantly ABP (p = 0.735). Conclusions Labetalol produced a reliable and titratable decrease in ABP with non significant increase in HR.

Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial

Brain Sciences, Free Full-Text

Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study

Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms

A systematic review of nicardipine vs labetalol for the management of hypertensive crises.

Blood Pressure Control With Labetalol Fails to Decrease Infection Risk in Intracerebral Hemorrhage - Neurovascular Exchange

Evaluation of presentation, treatment and outcome in hypertensive emergency in dogs and cats: 15 cases (2003‐2019) - Beeston - 2022 - Journal of Small Animal Practice - Wiley Online Library

Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients - Raywat Noiphithak, Gahn Duangprasert, Sasikan Sukhor, Pichayaphong Durongkaweroj, Vich Yindeedej, 2023

Antihypertensives in Pregnancy - Obstetrics and Gynecology Clinics